Christine A. Pratilas

Integrated ex vivo screening and transcriptomic profiling to prioritize drug combinations for rare cancers

The paper develops EXACT, a framework combining ex vivo drug screening with transcriptomic analysis to identify effective drug combinations for rare cancers, finding a MEK and HDAC inhibitor combination shows enhanced activity.

ZNF423 depletion induces the integrated stress response and represents a potential vulnerability in NF1-associated MPNST

This study shows ZNF423 depletion triggers the integrated stress response and sensitizes NF1-associated MPNST to chemotherapy, identifying it as a potential therapeutic target.

Multi-omics integration of malignant peripheral nerve sheath tumors identifies potential targets based on chromosome 8q status

This study integrates multi-omics data from MPNSTs to identify drug targets based on chromosome 8q status, suggesting PLK1 and EGFR inhibitors could be effective in different subtypes.

Integrated genomic analysis of NF1-associated peripheral nerve sheath tumors: an updated biorepository dataset

The paper provides an integrated genomic analysis of NF1-associated peripheral nerve sheath tumors using RNAseq and WES data from 73 and 114 samples, respectively, accessible via the NF Data Portal.

Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma

This study shows that combining SHP2 inhibition with BRAF inhibitors overcomes resistance in BRAF V600E-driven gliomas by suppressing RAS/ERK signaling and preventing tumor growth.

Early detection of malignant and pre-malignant peripheral nerve tumors using cell-free DNA fragmentomics

This study uses plasma cfDNA fragmentomics to distinguish malignant, pre-malignant, and non-malignant NF1-associated peripheral nerve sheath tumors.

Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/P38 signaling

This study identifies epigenetic differences between cutaneous and plexiform neurofibromas that drive distinct RAS/MKK/P38 signaling and clinical behavior.

Integrative analysis identifies candidate tumor microenvironment and intracellular signaling pathways that define tumor heterogeneity in NF1

The paper uses statistical and machine learning methods to analyze NF1 tumor genomic data, identifying key signaling pathways and molecular features associated with different tumor types and potential drug targets.